There are numerous companies in the healthcare sector that have been outstanding performers on the stock exchange lately. Alas, Teva Pharmaceutical Industries (NYSE: TEVA) isn't one of them.
On Tuesday, May 3, the generic-drugs specialist published first-quarter results that showed notable declines in some of its fundamentals. Perhaps this marks the start of an even tougher bear market for the stock.
For the quarter, Teva's revenue fell by 8% on a year-over-year basis to $3.66 billion. The company's non- GAAP (adjusted) net profit also saw a slide, declining at a 13% clip to land at $609 million, or $0.55 per share.
For further details see:
Teva's Q1 Results: Is the Stock About to Crash?